8:15 AM
 | 
Sep 01, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

EC approves Bioepis' Humira biosimilar

Samsung Bioepis Co. Ltd. said the European Commission approved Imraldi (SB5), a biosimilar of autoimmune drug Humira adalimumab. The biosimilar is indicated to treat psoriasis, Crohn's disease, rheumatoid arthritis,...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >